Evommune (Series C)
Funding Details
- Awarder
- Inbox
- Date Award
- October 31, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $115,000,000
Company Info
- Traction
- Evommune has raised over $130 million in previous funding rounds and is expecting three Phase 2 readouts in urticaria and eczema over the next two years.
- Founders
- Luis Pena
- Company Description
- Evommune is a biotechnology startup focused on developing drugs for chronic immune conditions, specifically targeting mast cell-driven diseases. The company is advancing a pipeline of therapies, including EVO756 for chronic urticaria and EVO301 for atopic dermatitis.
- Market
- Chronic immune conditions
- Location
- Palo Alto, California, United States
- Coinvestors
- RA Capital Management, Sectoral Asset Management